The iShares MSCI World ETF (URTH) is navigating a market of extremes. While its heavyweight financial holdings are posting historic profits, the fund itself faces intensifying pressure on its pricing strategy from a wave of low-cost competitors.
Morgan Stanley delivered a standout performance, with net income surging 29% to $5.57 billion. This capped a remarkable quarter for the sector, where overall earnings are projected to grow nearly 20% year-over-year. The bank’s investment banking profit jumped 36%, and its net revenue surpassed $20 billion for the first time in Q1 2026. JPMorgan Chase set a high bar earlier with record trading revenue of $11.6 billion, beating earnings-per-share estimates by about nine percent. Despite this strength, JPMorgan’s stock dipped nearly three percent after it slightly lowered its full-year net interest income forecast to $103 billion.
This financial sector momentum provides broad market support. FactSet analysts anticipate S&P 500 earnings growth of 12.5%, which would mark a sixth consecutive quarter of double-digit expansion.
Yet, the fee structure of the iShares ETF is under scrutiny. Invesco recently slashed the management fee for its competing MSCI World ETF to a razor-thin 0.05%. This move follows similar cuts by UBS to 0.06% in May 2025 and a BNP Paribas relaunch at 0.05% in September 2025. BlackRock, however, maintains a total expense ratio of 0.24% for its iShares product, a 19-basis-point premium to the cheapest rival. The asset manager justifies this with an exceptionally low tracking difference of just 0.02%. Some major institutions appear unconcerned; the Royal Bank of Canada increased its position by 17.5% to roughly two million shares in Q4 2025.
Should investors sell immediately? Or is it worth buying MSCI World ETF?
Beyond fees, macroeconomic risks are building. The US government imposed tariffs of up to 100% on imported patented pharmaceuticals in early April. Analysts calculate this measure could dampen global growth and push inflation up by approximately 0.5 percentage points. Further pressure is expected from additional tariffs on imported pharma products set for late July 2026, threatening significant margin compression for health sector constituents.
The ETF’s underlying index is also poised for change. In May, MSCI will implement a new free-float classification system with three categories. Market observers anticipate significantly larger portfolio reshuffles compared to the first quarter, which saw only 18 additions and 27 deletions. In a separate strategic move, MSCI is expanding into private markets with the acquisition of data specialist PM Insights, which provides daily reference data for non-listed company stakes with an estimated market cap exceeding $5.5 trillion.
Technology remains the portfolio’s dominant force, accounting for over 26% of its weight. Nvidia leads individual holdings at 5.29%, followed by Apple (4.55%) and Microsoft (3.16%). Together, these three tech giants command a 13.6% portfolio weighting.
Income-focused investors are looking ahead to June 15, 2026, when the ETF will trade ex-dividend. This follows a year where dividend growth exceeded the 20% mark. The fund’s immediate trajectory hinges on whether the continued strength from its tech titans and booming banks can offset the structural challenges of new tariffs and a relentless fee war.
Ad
MSCI World ETF Stock: Buy or Sell?! New MSCI World ETF Analysis from April 15 delivers the answer:
The latest MSCI World ETF figures speak for themselves: Urgent action needed for MSCI World ETF investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 15.
MSCI World ETF: Buy or sell? Read more here...
